ZA9010452B - Pharmaceutical preparation for oral administration in fluid form - Google Patents

Pharmaceutical preparation for oral administration in fluid form

Info

Publication number
ZA9010452B
ZA9010452B ZA9010452A ZA9010452A ZA9010452B ZA 9010452 B ZA9010452 B ZA 9010452B ZA 9010452 A ZA9010452 A ZA 9010452A ZA 9010452 A ZA9010452 A ZA 9010452A ZA 9010452 B ZA9010452 B ZA 9010452B
Authority
ZA
South Africa
Prior art keywords
oral administration
pharmaceutical preparation
fluid form
psychotropic
granules
Prior art date
Application number
ZA9010452A
Other languages
English (en)
Inventor
Gerrit Bernardus Maria Beuving
Bernardus Maria Beuving Gerrit
Henrik De Nijs
De Nijs Henrik
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of ZA9010452B publication Critical patent/ZA9010452B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9010452A 1989-12-30 1990-12-28 Pharmaceutical preparation for oral administration in fluid form ZA9010452B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL8903199 1989-12-30

Publications (1)

Publication Number Publication Date
ZA9010452B true ZA9010452B (en) 1991-10-30

Family

ID=19855853

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9010452A ZA9010452B (en) 1989-12-30 1990-12-28 Pharmaceutical preparation for oral administration in fluid form

Country Status (14)

Country Link
US (1) US5238688A (xx)
EP (1) EP0436252B1 (xx)
JP (1) JP3051459B2 (xx)
KR (1) KR0156735B1 (xx)
AT (1) ATE93136T1 (xx)
AU (1) AU634614B2 (xx)
CA (1) CA2033418C (xx)
DE (1) DE69002822T2 (xx)
DK (1) DK0436252T3 (xx)
ES (1) ES2060001T3 (xx)
IE (1) IE63986B1 (xx)
NZ (1) NZ236626A (xx)
PT (1) PT96401B (xx)
ZA (1) ZA9010452B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328688A (en) * 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
BR9909357A (pt) * 1998-04-02 2000-12-12 Akzo Nobel Nv Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
US6492320B2 (en) * 1999-09-24 2002-12-10 Rohm And Hass Company Multifunctional, granulated pellet aid and process
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
JP4619658B2 (ja) * 2002-03-12 2011-01-26 富山化学工業株式会社 快い味の経口懸濁液および方法
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US20070298107A1 (en) * 2003-11-25 2007-12-27 Aurobindo Pharma Ltd. Pharmaceutical Compositions of Mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128641A (en) * 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
NL7809726A (nl) * 1978-09-26 1980-03-28 Akzo Nv Nieuwe tetracyclische verbindingen.
JPS5665825A (en) * 1979-10-31 1981-06-03 Mochida Pharmaceut Co Ltd Remedy for peptic ulcer
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
ATE71293T1 (de) * 1986-09-18 1992-01-15 London Pharmacy Innovation Arzneiformulierung.
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
EP0319061A1 (en) * 1987-11-28 1989-06-07 Akzo N.V. Medicament with antiemetic action

Also Published As

Publication number Publication date
ES2060001T3 (es) 1994-11-16
IE63986B1 (en) 1995-06-28
DK0436252T3 (da) 1993-12-27
KR910011266A (ko) 1991-08-07
NZ236626A (en) 1992-10-28
EP0436252A1 (en) 1991-07-10
ATE93136T1 (de) 1993-09-15
US5238688A (en) 1993-08-24
CA2033418A1 (en) 1991-07-01
IE904531A1 (en) 1991-07-03
JPH04210638A (ja) 1992-07-31
KR0156735B1 (ko) 1998-11-16
DE69002822D1 (de) 1993-09-23
JP3051459B2 (ja) 2000-06-12
PT96401A (pt) 1991-10-15
AU6839890A (en) 1991-07-04
PT96401B (pt) 1998-06-30
AU634614B2 (en) 1993-02-25
EP0436252B1 (en) 1993-08-18
CA2033418C (en) 2002-05-14
DE69002822T2 (de) 1993-12-23

Similar Documents

Publication Publication Date Title
DE69330672D1 (de) Pharmazeutische zubereitung zur anwendung in den atemwegen
GR3035045T3 (en) Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof.
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
IL83059A0 (en) Stable cephalosporin derivatives,process for the preparation thereof and a gelatine capsule composition containing the same
HK1040631A1 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues.
DE69017915T2 (de) Zubereitung für den magen.
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
ZA9010452B (en) Pharmaceutical preparation for oral administration in fluid form
EP0141300A3 (en) An occulusion compound of 2-nitroxymethyl-6-chloropyridine with beta-cyclodextrin and process for preparation thereof
EP0357793A4 (en) Suspended-release preparation prepared by using alginic acid
IL103516A0 (en) Cytotoxic bicyclo(7,3,1)tridec-4-ene-2,6-diyne compounds,process for the preparation thereof and pharmaceutical compositions containing them
AU638083B2 (en) Swallowable dosage units comprising colloidal bismuth subcitrate
HUT49808A (en) Process for producing retarde pharmaceutical compositions containing aselastine
SE8400723D0 (sv) Farmaceutisk komposition
ZA897541B (en) Benzoxazolinone derivatives,process for the preparation thereof and pharmaceutical compositions containing them
CS240991A3 (en) Solid forms for oral administration, said forms containing iphosphamide as active component
DE69017839D1 (de) NMDA-blockierende Verbindungen, pharmazeutische Präparate, deren Herstellung und Verwendung.
IL113167A0 (en) A sustained release pharmaceutical excipient containing a heteropolysaccharide gum and methods for the preparation thereof
ZA947401B (en) Use of partially methylated beta-cyclodextrins as absorption promoters in the preparation of pharmaceutical compositions for the transcutaneous administration of active principles
SE8106498L (sv) Kvaternera salter av n,n3-di(beta-brompropionyl)-n1,n2-dispirotripiperazinium, forfarande for framstellning av desamma och lekemedelspreparat innehallande desamma
EP0425362A3 (en) Furosemide salts, process for their preparation, their use as medicines and pharmaceutical compositions containing them
HU892236D0 (en) Process for the preparation of (d)-2,3-dihydro-2',5'-dioxo-6-fluoro-spiro(4h-1-benzopyran-4,4-imidazolidin)-2-carboxamide derivatives and pharmaceutical compositions containing them
RU93042104A (ru) Противокашлевая композиция, содержащая декстрометорфан, способ ее применения
NO964775L (no) Fast farmasöytisk adenosinholdig preparat